Načítá se...
Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
Optimization of post‐remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents...
Uloženo v:
| Vydáno v: | Am J Hematol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6593671/ https://ncbi.nlm.nih.gov/pubmed/30945331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25484 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|